

**MINUTES OF THE October 12th, 2010
PHARMACY AND THERAPEUTICS (P&T) COMMITTEE MEETING**

MEMBERS ATTENDING: Hosan Azomani, M.D.; Joyce Brewer, Ph.D.; Sharon Dickey, Pharm.D.; Ryan Harper Pharm.D.; Lonnie Hicks, R.Ph.; Deborah Minor, Pharm.D.; John Mitchell M.D.; Carol Tingle, M.D.; Lee Voulters M.D.; Geri Lee Wieland M.D.; Wilma Wilbanks, R.Ph.

Also present: Judith Clark, R.Ph., Pharmacy Director, DOM; Terri Kirby, R.Ph., DOM; J. David Wuest, R.Ph., Provider Synergies

MEMBERS ABSENT: Billy Brown, Pharm.D.;

CALL TO ORDER: Dr. Minor called the meeting to order.

INTRODUCTIONS: Ms. Clark welcomed attendees to the meeting. She introduced new members, John Mitchell, M.D. and Geri Lee Wieland, M.D. She requested that everyone at the table introduce themselves. She thanked the Committee members for their work and introduced the DOM pharmacy staff and attendees from DOM's other pharmacy vendors, HID and ACS. ACS staff participated in the meeting via tele-conference.

ADMINISTRATIVE MATTERS: Ms. Clark outlined procedural and safety guidelines for the meeting. She noted that the P&T Committee is an advisory committee and that the DOM has the final say regarding the PDL. She stated that the PDL decisions for classes reviewed at this meeting will be post at the website by December 1, 2010, and will become effective on January 1, 2011. She announced the 2011 P&T schedule and provided copies of the schedule to the Committee members and the public. Ms. Clark provided updates on the new DUR process, a more user friendly 72 hour emergency medication override, plans to improve the State's electronic prior authorization program and EPDST access.

Leslie Leon, Pharm.D., Clinical Pharmacist, presented an overview of ACS's emergency 72 hour POS override program and implementation of a SMART PA process for pharmacy claims.

DRUG CLASS ANNOUNCEMENTS: Ms. Clark stated that DOM and Provider Synergies continually review drug classes for the PDL process based on the clinical and financial benefits. She informed the Committee that the Cough and Cold class will be reviewed at this meeting. She provided the Committee with an overview on the current policy regarding Cough and Cold agents. The Committee was instructed that there is no guarantee that DOM will alter their current policy regarding coverage of additional cough and cold preparations. However, the DOM is requesting the Committee's direction and recommendations. She thanked the Committee in advance for providing assistance in the class of medications.

APPROVAL OF SEPTEMBER 14TH, 2010 MEETING MINUTES: Dr. Minor asked for changes or a motion to approve the minutes from the September 14, 2010, P&T Committee meeting. Dr. Harper requested that typographical errors be fixed and he motioned that the minutes be approved. Mr. Hicks seconded the motion and the minutes were approved unanimously.

PRESENTATIONS BY ADVOCACY GROUPS: Elisa Smith, Registered Dietician spoke regarding Medicaid recipient access to nutritional products on behalf of The Mississippi Dietetics Association

THERAPEUTIC CLASS REVIEWS: Mr. Wuest stated that he will be presenting new information not previously covered in the Committee's reviews.

Michael W. Jann, Pharm.D. presented clinical information regarding Suboxone on behalf of Reckitt Benckiser.

ACNE AGENTS, TOPICAL

Mr. Wuest presented a brief overview of this class. Mr. Wuest presented the PDL recommendations for the class:

Brand Name	Current PDL Status	PDL Recommendation
BENZOYL PEROXIDE OTC (TOPICAL)	ON	Yes-Generic
BENZOYL PEROXIDE (TOPICAL)	ON	Yes-Generic
RETIN-A MICRO (TOPICAL)	ON	Yes
AZELEX (TOPICAL)	ON	Yes
AKNE-MYCIN (TOPICAL)	OFF	No
ERYTHROMYCIN (TOPICAL)	ON	Yes-Generic
CLINDAMYCIN PHOSPHATE (TOPICAL)	ON	Yes-Generic
SULFACETAMIDE / SULFUR (TOPICAL)	ON	Yes-Generic
BPO/SULFUR (TOPICAL)	OFF	No-Generic
NUOX (TOPICAL)	ON	Yes
DIFFERIN (TOPICAL)	OFF	No
TAZORAC (TOPICAL)	OFF	No
ZACLIR (TOPICAL)	ON	Yes
BENZACLIN (TOPICAL)	ON	Yes
TRETINOIN (TOPICAL)	OFF	No-Generic
CLINAC BPO (TOPICAL)	ON	Yes
SE BPO (TOPICAL)	OFF	No
EVOCLIN (TOPICAL)	OFF	No
SULFACETAMIDE (TOPICAL)	OFF	No-Generic
ACANYA (TOPICAL)	OFF	No
INOVA (TOPICAL)	ON	Yes
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	OFF	No-Generic
ATRALIN (TOPICAL)	OFF	No
ACZONE (TOPICAL)	OFF	No
DUAC (TOPICAL)	OFF	No
CLARIFOAM EF (TOPICAL)	OFF	No
CLINDAMYCIN / BENZOYL PEROXIDE (TOPICAL)	OFF	No-Generic
BENZEFOAM (TOPICAL)	OFF	No
ZIANA (TOPICAL)	OFF	No
ADAPALENE GEL (TOPICAL)	OFF	No-Generic
EPIDUO (TOPICAL)	OFF	No
ADAPALENE CREAM (TOPICAL)	OFF	No-Generic

No public testimony on this class was provided.

Dr. Brewer made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Ms. Wilbanks. The motion passed unanimously.

ANALGESICS, NARCOTICS LONG

Mr. Wuest noted that Exalgo has entered the market since the last time the Committee reviewed this class. He provided an overview of the new agent and the class.

Mr. Wuest presented the PDL recommendations for the class.

Brand Name	Current PDL Status	PDL Recommendation
METHADONE (ORAL)	ON	Yes-Generic
DURAGESIC MATRIX (TRANSDERM.)	OFF	No
KADIAN (ORAL)	ON	Yes
MORPHINE ER (ORAL)	ON	Yes-Generic
DURAGESIC (TRANSDERM.)	ON	Yes
ULTRAM ER (ORAL)	OFF	No
TRAMADOL ER (ORAL)	OFF	No-Generic
RYZOLT (ORAL)	OFF	No
OPANA ER (ORAL)	OFF	No
AVINZA (ORAL)	OFF	No
EMBEDA (ORAL)	OFF	No
FENTANYL (TRANSDERM)	ON	Yes-Generic
OXYCONTIN (ORAL)	OFF	No
EXALGO (ORAL)	OFF	No
OXYCODONE ER (ORAL)	OFF	No-Generic

No public testimony on this class was provided.

Dr. Azomani made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Dr. Brewer. The motion passed unanimously.

ANALGESICS, NARCOTICS SHORT

Mr. Wuest presented a brief overview of the class including an update of FDA advisory committee recommendation.

Mr. Wuest presented the following PDL recommendations for the class:

Brand Name	Current PDL Status	PDL Recommendation
TRAMADOL (ORAL)	ON	Yes-Generic
PROPOXYPHENE / APAP (ORAL)	ON	Yes-Generic
APAP / CODEINE (ORAL)	ON	Yes-Generic
MEPERIDINE (ORAL)	ON	Yes-Generic
CODEINE (ORAL)	ON	Yes-Generic
HYDROCODONE / APAP (ORAL)	ON	Yes-Generic
PROPOXYPHENE (ORAL)	OFF	No-Generic
MORPHINE IR (ORAL)	ON	Yes-Generic
HYDROMORPHONE (ORAL)	ON	Yes-Generic
OXYCODONE / ASA (ORAL)	ON	Yes-Generic
DARVON-N (ORAL)	OFF	No
OXYCODONE / APAP (ORAL)	ON	Yes-Generic
OXYCODONE / IBUPROFEN (ORAL)	ON	Yes-Generic
REPREXAIN (ORAL)	OFF	No
HYDROCODONE / IBUPROFEN (ORAL)	ON	Yes-Generic
TRAMADOL / APAP (ORAL)	ON	Yes-Generic
PENTAZOCINE / APAP (ORAL)	ON	Yes-Generic
IBUDONE (ORAL)	ON	Yes
ZAMICET (ORAL)	OFF	No
DILAUDID LIQUID (ORAL)	OFF	No
OXYCODONE (ORAL)	ON	Yes-Generic
DIHYDROCODEINE / APAP / CAFFEINE (ORAL)	ON	Yes-Generic
BUTALBITAL COMPOUND W/CODEINE (ORAL)	OFF	No-Generic
PENTAZOCINE / NALOXONE (ORAL)	OFF	No-Generic
RYBIX ODT (ORAL)	OFF	No
HYCET (ORAL)	OFF	No
LEVORPHANOL (ORAL)	OFF	No-Generic
NUCYNTA (ORAL)	OFF	No
XODOL (ORAL)	OFF	No
OPANA (ORAL)	OFF	No
FENTORA (BUCCAL)	OFF	No
FENTANYL (BUCCAL)	OFF	No-Generic
ONSOLIS (BUCCAL)	OFF	No

No public testimony on this class was provided.

Dr. Dickey made a motion to accept the recommendations as presented. Dr. Harper seconded the motion, which passed unanimously.

ANALGESICS-ANESTHETICS, TOPICAL

Mr. Wuest noted that Pennsaid has entered the market since the last time the Committee reviewed this class. He provided an overview of the new agent and the class.

Mr. Wuest presented the PDL recommendations for the class:

Brand Name	Current PDL Status	PDL Recommendation
VOLTAREN (TOPICAL)	ON	Yes
PENNSAID (TOPICAL)	OFF	No
FLECTOR (TOPICAL)	ON	Yes
LIDODERM (TOPICAL)	ON	Yes

No public testimony on this class was provided. Tina Dancer, Pharm.D. yielded her time to the Committee on behalf of King.

Dr. Voulters made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Dr. Azomani. The motion passed unanimously.

ANTIFUNGALS, TOPICAL

Mr. Wuest presented a brief overview of the class including clinical information about the new agent in this class, Bensal HP.

Mr. Wuest then presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
NYSTATIN-TRIAMCINOLONE (TOPICAL)	ON	Yes-Generic
TERBINAFINE OTC (TOPICAL)	ON	Yes-Generic
NYSTATIN (TOPICAL)	ON	Yes-Generic
TOLNAFTATE OTC (TOPICAL)	ON	Yes-Generic
CLOTRIMAZOLE OTC (TOPICAL)	ON	Yes-Generic
MICONAZOLE OTC (TOPICAL)	ON	Yes-Generic
NAFTIN (TOPICAL)	ON	Yes
EXELDERM (TOPICAL)	OFF	No
KETOCONAZOLE (TOPICAL)	OFF	No-Generic
KETOCONAZOLE SHAMPOO (TOPICAL)	ON	Yes-Generic
CLOTRIMAZOLE RX (TOPICAL)	ON	Yes-Generic
OXISTAT (TOPICAL)	OFF	No
CLOTRIMAZOLE-BETAMETHASONE (TOPICAL)	ON	Yes-Generic
ECONAZOLE (TOPICAL)	ON	Yes-Generic
ERTACZO (TOPICAL)	OFF	No
VUSION (TOPICAL)	OFF	No
CICLOPIROX CR/SUSP/GEL (TOPICAL)	ON	Yes-Generic
LAMISIL SOLUTION (TOPICAL)	ON	Yes
XOLEGEL (TOPICAL)	OFF	No
MENTAX (TOPICAL)	OFF	No
CICLOPIROX SHAMPOO (TOPICAL)	OFF	No-Generic
BENSAL HP (TOPICAL)	OFF	No
CICLOPIROX SOLUTION (TOPICAL)	OFF	No-Generic
EXTINA (TOPICAL)	OFF	No
KETOCON + PLUS (TOPICAL)	OFF	No
CNL 8 (TOPICAL)	OFF	No

No public testimony on this class was provided.

Dr. Brewer made a motion to approve the recommendations as presented by Provider Synergies. The motion was seconded by Dr. Tingle and passed unanimously.

ANTIHYPURICEMICS

Mr. Wuest noted that Colcrys has entered the market since the last time the Committee reviewed this class and it is expected that generic colchicine will leave the market by the end of the year. He provided an overview of the new agent and the class.

Mr. Wuest presented the PDL recommendations for this class:

Brand Name	Current PDL Status	PDL Recommendation
ALLOPURINOL (ORAL)	ON	Yes-Generic
COLCHICINE (ORAL)	ON	Yes-Generic
PROBENECID (ORAL)	ON	Yes-Generic
PROBENECID / COLCHICINE (ORAL)	ON	Yes-Generic
ULORIC (ORAL)	OFF	No
COLCRYS (ORAL)	OFF	No

Public testimony on this class was provided on Colcrys by Arleen Decicco, Pharm.D. on behalf of URL Pharma.

Dr. Azomani made the motion to approve the recommendations as presented by Provider Synergies with the understanding that one colchicine product should be preferred. The motion was seconded by Dr. Weiland and passed unanimously.

ANTIMIGRAINE AGENTS

Mr. Wuest noted that this class has no new agents in it since the last time the Committee reviewed it. He provided an overview of the class.

Mr. Wuest presented the PDL recommendations:

Brand Name	Current PDL Status	PDL Recommendation
MAXALT MLT (ORAL)	OFF	No
IMITREX (NASAL)	ON	No
IMITREX (SUBCUTANE.)	ON	No
RELPAK (ORAL)	ON	Yes
AXERT (ORAL)	OFF	No
FROVA (ORAL)	OFF	No
TREXIMET (ORAL)	ON	Yes
MAXALT / MLT (ORAL)	OFF	No
ZOMIG / ZOMIG ZMT (ORAL)	OFF	No
ZOMIG (NASAL)	OFF	No
CAMBIA (ORAL)	OFF	No
SUMATRIPTAN (ORAL)	ON	Yes-Generic
IMITREX (ORAL)	ON	No
NARATRIPTAN (ORAL)	OFF	No-Generic
SUMATRIPTAN (NASAL)	ON	Yes-Generic
SUMATRIPTAN (SUBCUTANE.)	ON	Yes-Generic

Public testimony on this class was provided on Treximet by Vivian Tucker, Pharm.D. on behalf of GSK.

Dr. Voulters made a motion to accept the recommendations as presented. The motion was seconded by Dr. Brewer. The motion passed unanimously.

ANTIPARASITICS, TOPICAL

Mr. Wuest presented an overview of the class which is a new class to the Committee.

Mr. Wuest presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
PERMETHRIN OTC (TOPICAL)	ON	Yes-Generic
PERMETHRIN (TOPICAL)	ON	Yes-Generic
EURAX (TOPICAL)	ON	Yes
ULESFIA (TOPICAL)	OFF	No
LINDANE (TOPICAL)	OFF	No-Generic
MALATHION (TOPICAL)	ON	Yes-Generic
OVIDE (TOPICAL)	OFF	No

Public testimony on this class was provided on Ulesfia by Kenneth Jackson on behalf of Shionogi and on Malathion and Ovide by David Benningfield on behalf of Taro Pharma.

Dr. Azomani made a motion to accept the recommendations as presented. The motion was seconded by Dr. Weiland and passed unanimously.

ANTIVIRALS, TOPICAL

No clinical information was presented on this class.

No public testimony on this class was provided.

Dr. Azomani made a motion to review this class at the next meeting. The motion was seconded by Dr. Weiland and passed unanimously

CYTOKINE AND CAM ANTAGONISTS

Mr. Wuest presented overview of this therapeutic class.

Mr. Wuest presented multiple PDL recommendations for the class. The Committee decided to utilize the following recommendation:

Brand Name	Current PDL Status	PDL Recommendation
ENBREL (INJECTION)	ON	Yes
HUMIRA (INJECTION)	ON	Yes
CIMZIA (INJECTION)	ON	No
ORENCIA (INJECTION)	OFF	No
ACTEMRA (INJECTION)	OFF	No
KINERET (INJECTION)	ON	Yes
SIMPONI (INJECTION)	OFF	No
AMEVIVE (INJECTION)	OFF	No
STELARA (INJECTION)	OFF	No
REMICADE (INJECTION)	OFF	No

Public testimony on this class was provided on Stelara and Simponi by Megan Jones, Pharm.D. on behalf of Johnson & Johnson and on Cimzia by Jay Vollett, M.D. on behalf of UCB. Pam Sardo, Pharm.D. yielded her time to the Committee on behalf of Abbott and Sanjay Mehta, Pharm.D. yielded his time to the Committee on behalf of Amgen.

Dr. Azomani made a motion to accept the recommendations as presented. The motion was seconded by Dr. Harper and passed unanimously.

FIBROMYALGIA

Mr. Wuest presented a brief overview of the class which is a new class to the committee.

Brand Name	Current PDL Status	PDL Recommendation
SAVELLA (ORAL)	ON	Yes
LYRICA (ORAL)	ON	Yes
CYMBALTA (ORAL)	OFF	No

Public testimony on this class was provided on Cymbalta by Esther Liu, Pharm.D. on behalf of Lilly. Arlene Cerbone yielded her time to the Committee on behalf of Forrest and Lee Ann Griffin, Pharm.D. yielded his time to the Committee on behalf of Pfizer.

Dr. Harper made a motion to accept the recommendations as presented. The motion was seconded by Dr. Azomani and passed by 10 to 1 vote. Ms. Wilbanks was opposed.

IMMUNOMODULATORS, ATOPIC DERMATITIS

Mr. Wuest presented an overview of the class. There are no new agents in this class since the last time the Committee review the class.

Mr. Wuest made the following recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
PROTOPIC (TOPICAL)	ON	Yes
ELIDEL (TOPICAL)	ON	Yes

No public testimony on this class was provided. Marilyn Ripoll yielded her time to the Committee on behalf of Astellas.

Dr. Dickey made a motion to accept the recommendations as presented. The motion was seconded by Mr. Hicks and passed unanimously by the Committee.

NSAIDS

Mr. Wuest noted that Vimovo has entered the market since the last time the Committee reviewed this class. He provided an overview of the new agent and the class.

Mr. Wuest made the following recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
PIROXICAM (ORAL)	ON	Yes-Generic
IBUPROFEN RX (ORAL)	ON	Yes-Generic
MELOXICAM (ORAL)	ON	Yes-Generic
KETOPROFEN (ORAL)	ON	Yes-Generic
FLURBIPROFEN (ORAL)	ON	Yes-Generic
KETOROLAC (ORAL)	ON	Yes-Generic
NAPROXEN (ORAL)	ON	Yes-Generic
INDOCIN SUSPENSION (ORAL)	OFF	No
SULINDAC (ORAL)	ON	Yes-Generic
DICLOFENAC (ORAL)	ON	Yes-Generic
ETODOLAC (ORAL)	ON	Yes-Generic
INDOMETHACIN (ORAL/RECTAL)	ON	Yes-Generic
FENOPROFEN (ORAL)	ON	Yes-Generic
OXAPROZIN (ORAL)	ON	Yes-Generic
ARTHROTEC (ORAL)	OFF	No
NABUMETONE (ORAL)	OFF	No-Generic
CELEBREX (ORAL)	OFF	No
VIMOVO (ORAL)	OFF	No
TOLMETIN (ORAL)	OFF	No-Generic
MECLOFENAMATE (ORAL)	OFF	No-Generic
ZIPSOR (ORAL)	OFF	No
INDOCIN (RECTAL)	OFF	No

Public testimony on this class was provided on Vimovo by Kim Lonergan on behalf of Astra Zeneca and on Celebrex by Lee Ann Griffin, Pharm.D. on behalf of Pfizer.

Dr. Azomani made a motion to approve the PDL as recommended. The motion was seconded by Ms. Wilbanks and was passed unanimously.

NUTRITIONALS, CALORIC AGENTS

Mr. Wuest presented clinical data on agents in this class. He also provided an overview on how this class has been compared by the call center at the request of providers.

Mr. Wuest made the following recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
POLYCOSE (ORAL)	ON	Yes
DUOCAL (ORAL)	ON	Yes
PROMOD (ORAL)	ON	Yes
RESOURCE (ORAL)	ON	Yes
SCANDISHAKE (ORAL)	NR	Yes
JUVEN (ORAL)	ON	Yes
NUTRITIONAL SUPPLEMENT (ORAL)	NR	Yes-Generic
BRIGHT BEGINNINGS (ORAL)	ON	Yes
BOOST (ORAL)	ON	Yes
ENSURE (ORAL)	ON	Yes
CARNATION INSTANT BREAKFAST (ORAL)	ON	Yes
TWOCAL HN (ORAL)	ON	Yes
NUTREN (ORAL)	ON	Yes
OSMOLITE (ORAL)	ON	Yes
PEDIASURE (ORAL)	ON	Yes
FIBERSOURCE (ORAL)	OFF	No
ISOSOURCE (ORAL)	OFF	No
JEVITY (ORAL)	OFF	No
PROMOTE (ORAL)	OFF	No
EO28 SPLASH (ORAL)	OFF	No
COMPLEAT (ORAL)	OFF	No
VITAL (ORAL)	OFF	No
VIVONEX (ORAL)	NR	No
TOLEREX (ORAL)	OFF	No
PEPTAMEN (ORAL)	NR	No

Public testimony on this class was provided by Pam Roberts, R.D. on behalf of Ross Labs.

Dr. Harper made a motion to accept the recommendations as presented. Dr. Dickey seconded the motion, which passed unanimously.

SKELETAL MUSCLE RELAXANTS

Mr. Wuest presented an overview of this class.

He presented the following recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
CARISOPRODOL (ORAL)	OFF	No-Generic
CHLORZOXAZONE (ORAL)	ON	Yes-Generic
CYCLOBENZAPRINE (ORAL)	ON	Yes-Generic
BACLOFEN (ORAL)	ON	Yes-Generic
CARISOPRODOL COMPOUND (ORAL)	OFF	No-Generic
METHOCARBAMOL (ORAL)	ON	Yes-Generic
TIZANIDINE (ORAL)	ON	Yes-Generic
ORPHENADRINE (ORAL)	OFF	No-Generic
AMRIX (ORAL)	OFF	No
ORPHENADRINE COMPOUND (ORAL)	OFF	No-Generic
DANTROLENE SODIUM (ORAL)	ON	Yes-Generic
SKELAXIN (ORAL)	OFF	No
SOMA 250 MG (ORAL)	OFF	No
ZANAFLEX CAPSULES (ORAL)	OFF	No
FEXMID (ORAL)	OFF	No
METAXALONE (ORAL)	OFF	No-Generic

No public testimony on this class was provided.

Dr. Dickey made a motion to accept the recommendations as presented. Dr. Voulters seconded the motion, which passed unanimously.

STEROIDS, TOPICAL HIGH

Mr. Wuest stated that there is no significant new clinical information to present for this class, but he did provide an overview of the class.

Mr. Wuest presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
TRIAMCINOLONE ACETONIDE (TOPICAL)	ON	Yes-Generic
BETAMETHASONE VALERATE (TOPICAL)	ON	Yes-Generic
FLUOCINONIDE EMOLLIENT (TOPICAL)	ON	Yes-Generic
FLUOCINONIDE-E (TOPICAL)	ON	Yes-Generic
FLUOCINONIDE (TOPICAL)	ON	Yes-Generic
BETAMETHASONE DIPROPIONATE (TOPICAL)	OFF	No-Generic
KENALOG AEROSOL (TOPICAL)	OFF	No
AMCINONIDE (TOPICAL)	OFF	No-Generic
HALOG (TOPICAL)	OFF	No
DIFLORASONE DIACETATE (TOPICAL)	OFF	No-Generic
VANOS (TOPICAL)	OFF	No
DESOXIMETASONE (TOPICAL)	OFF	No-Generic

No public testimony on this class was provided.

Dr. Tingle made a motion to approve the recommendations. The motion was seconded by Dr. Voulters. The motion was approved unanimously.

STEROIDS, TOPICAL LOW

Mr. Wuest stated that there is no significant new clinical information to present for this class, but he did provide an overview of the class.

Mr. Wuest presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
HYDROCORTISONE OTC (TOPICAL)	ON	Yes-Generic
HYDROCORTISONE (TOPICAL)	ON	Yes-Generic
CAPEX SHAMPOO (TOPICAL)	ON	Yes
DESONIDE (TOPICAL)	ON	Yes-Generic
DERMA-SMOOTHIE-FS (TOPICAL)	OFF	No
ALCLOMETASONE DIPROPIONATE (TOPICAL)	OFF	No-Generic
DESONATE (TOPICAL)	OFF	No
PEDIADERM HC (TOPICAL)	OFF	No
VERDESO (TOPICAL)	OFF	No
DESONIL + PLUS (TOPICAL)	OFF	No

Public testimony on this class was provided on Derma-Smoothe-FS by Jerry Wells, R.Ph. on behalf of Hill Dermaceuticals.

Dr. Dingle made a motion to approve the recommendations. The motion was seconded by Ms. Wilbanks. The motion was approved unanimously.

STEROIDS, TOPICAL MEDIUM

Mr. Wuest stated that there is no significant new clinical information to present for this class, but he did provide an overview of the class.

Mr. Wuest presented multiple PDL recommendations for the class. The Committee decided to utilize the following recommendation:

Brand Name	Current PDL Status	PDL Recommendation
PANDEL (TOPICAL)	NR	Yes
CLODERM (TOPICAL)	OFF	No
FLUOCINOLONE ACETONIDE (TOPICAL)	ON	Yes-Generic
HYDROCORTISONE VALERATE (TOPICAL)	ON	Yes-Generic
MOMETASONE FUROATE (TOPICAL)	ON	Yes-Generic
HYDROCORTISONE BUTYRATE (TOPICAL)	ON	Yes-Generic
LUXIQ (TOPICAL)	ON	Yes
FLUTICASONE PROPIONATE (TOPICAL)	ON	No-Generic
PREDNICARBATE (TOPICAL)	ON	Yes-Generic
CORDRAN TAPE (TOPICAL)	OFF	No
CUTIVATE LOTION (TOPICAL)	OFF	No
MOMEXIN (TOPICAL)	ON	No
LOCOID LIPOCREAM (TOPICAL)	NR	No

No public testimony on this class was provided.

Dr. Voulters made a motion to approve the recommendations. The motion was seconded by Dr. Azomani. The motion was approved unanimously.

STEROIDS, TOPICAL VERY HIGH

Mr. Wuest stated that there is no significant new clinical information to present for this class, but he did provide an overview of the class.

Mr. Wuest presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
CLOBETASOL EMOLLIENT (TOPICAL)	ON	Yes-Generic
HALOBETASOL PROPIONATE (TOPICAL)	ON	Yes-Generic
CLOBETASOL PROPIONATE (TOPICAL)	ON	Yes-Generic
CLOBEX (TOPICAL)	OFF	No
HALONATE PAC (TOPICAL)	OFF	No-Generic
HALONATE (TOPICAL)	OFF	No-Generic
OLUX-E (TOPICAL)	OFF	No
OLUX-OLUX-E (TOPICAL)	OFF	No

No public testimony on this class was provided.

Dr. Tingle made a motion to approve the recommendations. The motion was seconded by Dr. Voulters. The motion was approved unanimously.

COUGH AND COLD AGENTS

Mr. Wuest presented a brief overview of the class. PDL recommendations were discussed but not presented.

Public testimony on this class was provided on Rymed and Ed-A Hist by Jim Smith on behalf of Edwards and on Clofera and Dical by Jackson Como, R.Ph. on behalf of Centrix.

Dr. Voulters made a motion to prefer agents that cost less than 10 dollars per prescription for the State to provide to recipients. The motion was seconded by Dr. Harper and passed unanimously by the Committee.

NEW AGENTS TO MARKET

Dr. Voulters left the meeting due to a prior commitment.

Mr. Wuest presented a brief overview of each agent including its place in the market.

Zuplenz

No public testimony on this class was provided.

Dr. Harper made a motion to approve the recommendations. The motion was seconded by Dr. Azomani. The motion was approved unanimously.

Mirepex ER

No public testimony on this class was provided.

Dr. Azomani made a motion to approve the recommendations. The motion was seconded by Ms. Wilbanks. The motion was approved unanimously.

Prolia

No public testimony on this class was provided.

Dr. Azomani made a motion to approve the recommendations. The motion was seconded by Dr. Weiland. The motion was approved unanimously.

Jalyn

Public testimony on this class was provided on Jalyn by Ronald Davis, M.D. on behalf of GSK.

Dr. Weiland made a motion to approve the recommendations with the addition of Jayln preferred. The motion was seconded by Dr. Mitchell. The motion was approved unanimously.

Dulera

Public testimony on this class was provided on Dulera by Jack Putman, M.D. on behalf of Merck.

Dr. Harper made a motion to approve the recommendations with the addition of Dulera preferred. The motion was seconded by Dr. Weiland. The motion was approved unanimously.

Livalo

No public testimony on this class was provided.

Dr. Brewer made a motion to approve the recommendations. The motion was seconded by Dr. Azomani. The motion was approved unanimously.

PDL STATUS OF AVANDIA

Mr. Wuest provided an overview of the FDA panel's safety alert on Avandia.

Ms. Clark provided an overview on Avandia utilization.

No public testimony on this class was provided.

Dr. Mitchell made a motion to recommend that Avandia be non-preferred. The motion was seconded by Dr. Harper. The motion was approved

unanimously. **OTHER BUSINESS**

There was no other business.

NEXT MEETING DATE

Ms. Clark stated that the next P&T Committee meeting is tentatively scheduled to be March, 2011.

ADJOURNMENT

There being no further business, Dr. Minor adjourned the meeting.